CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Michael Marks

CFO & Executive VP, HCA Healthcare

Search every verified Michael Marks interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Michael Marks, CFO and Executive Vice President of HCA Healthcare, has participated in the company's quarterly earnings calls through 2025 and 2026, where he discussed financial performance and guidance. In the Q4 2025 call, he outlined 2026 guidance that included an adverse impact on adjusted EBITDA of $600 million to $900 million related to health insurance exchanges, attributing this to administrative reforms from the One Big Beautiful Bill Act and the expiration of enhanced premium tax credits. He also noted an expected offset of approximately $400 million through resiliency initiatives. During the Q1 2026 call, he described a $180 million headwind in the quarter as "temporal and not structural," and mentioned a $200 million improvement for the full year from supplemental payment benefits in Georgia and Texas. In the Q2 2026 call, he stated that exchange volume declines of 15% in the first and second quarters were in line with original guidance estimates, and he expressed a belief that coverage losses in 2027 would be less than in 2026, assuming core premium tax credits continue without enhanced support. Marks has also addressed other financial topics in these calls. In Q2 2025, he noted that about half of a $300 million increase in guidance at midpoint came from state supplemental payment programs, including the approval of a new Tennessee program. He discussed payer contracting, stating in the Q4 2024 call that the company was 80% contracted for 2025, 60% for 2026, and 20% for 2027, and that efforts to manage denials and underpayments had been strengthened. He has also commented on cost pressures, noting in Q2 2025 that physician costs remained elevated, with same-facility professional fees up about 10% year-over-year, while clinical labor costs were described as stable.

Recent appearances

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →